NCT04584866

Brief Summary

This study is to prospectively compare the standard supine (control group) and the semi-sitting position (head elevation of 30°; intervention group) in endoscopic endonasal pituitary surgery.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
54

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Jan 2021

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 5, 2020

Completed
9 days until next milestone

First Posted

Study publicly available on registry

October 14, 2020

Completed
3 months until next milestone

Study Start

First participant enrolled

January 22, 2021

Completed
3.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 29, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 29, 2024

Completed
Last Updated

April 29, 2025

Status Verified

April 1, 2025

Enrollment Period

3.4 years

First QC Date

October 5, 2020

Last Update Submit

April 28, 2025

Conditions

Keywords

endoscopic endonasal pituitary surgeryendoscopic skull base surgeryintracranial venous pressurevenous air embolism

Outcome Measures

Primary Outcomes (2)

  • Intraoperative blood loss

    Intraoperative blood loss, calculated as follow: volume in the suction bag minus volume of rinsing water in Milliliters (ml). The surgery is divided into four steps: 1. endonasal phase, 2. osteodural exposure. 3. sellar stage and 4. skull base defect closure. For each step, the primary outcome will be assessed.

    Intraoperative

  • Frequency of interruption of the surgical workflow due to disturbing blood or a bleeding in the surgical field (number)

    Frequency of interruption of the surgical workflow due to disturbing blood or a bleeding in the surgical field. This will be assessed by an independent blinded neurosurgeon, who will watch the operative video after the surgery.

    During surgery

Secondary Outcomes (9)

  • Change in intraoperative Mean Arterial Pressure (MAP)

    Intraoperative

  • Amount of intravenous fluid administered during surgery (ml)

    Intraoperative

  • Need for vasoactive drugs (vasopressors) (number)

    at Day 1 (day of surgery)

  • Incidence of air embolism (number)

    at Day 1 (day of surgery)

  • Operative time (minutes)

    During surgery

  • +4 more secondary outcomes

Study Arms (2)

Study Intervention

ACTIVE COMPARATOR

Endonasal endoscopic pituitary surgery in semi-sitting position

Procedure: Endonasal endoscopic pituitary surgery in semi-sitting position

Control Intervention

ACTIVE COMPARATOR

Endonasal endoscopic pituitary surgery in supine position

Procedure: Endonasal endoscopic pituitary surgery in supine position

Interventions

Patients will be placed in semi-sitting position. To achieve the semi-sitting position, the patient is placed in supine position. The operating table is then separated and flexed to elevate the torso (angle of 30°). The head, which is fixed in a head clamp, is slightly flexed to bring the floor of the sella right in front of the surgeon and gently rotated toward the operating team.

Study Intervention

Patients will be operated in the standard supine neutral position

Control Intervention

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients with a presumed pituitary pathologies who are suitable for endoscopic endonasal surgical resection

You may not qualify if:

  • Patients with known hemorrhagic or thrombophilic disorders
  • Patients with conditions associated with high central venous pressure: congestive heart failure, pulmonary hypertension, chronic obstructive pulmonary disease (COPD), interstitial lung disease, pregnancy
  • Patients with poor cardiopulmonary condition (unable to perform 4 metabolic equivalents without stopping (climb a flight of stairs))

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Department of Neurosurgery, University Hospital Basel

Basel, 4031, Switzerland

Location

MeSH Terms

Conditions

Pituitary Neoplasms

Interventions

Supine Position

Condition Hierarchy (Ancestors)

Endocrine Gland NeoplasmsNeoplasms by SiteNeoplasmsHypothalamic NeoplasmsSupratentorial NeoplasmsBrain NeoplasmsCentral Nervous System NeoplasmsNervous System NeoplasmsBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesHypothalamic DiseasesPituitary DiseasesEndocrine System Diseases

Intervention Hierarchy (Ancestors)

PostureMusculoskeletal Physiological PhenomenaMusculoskeletal and Neural Physiological Phenomena

Study Officials

  • Jonathan Rychen

    Department of Neurosurgery, University Hospital Basel

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: prospective randomized single-blinded controlled superiority trial
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 5, 2020

First Posted

October 14, 2020

Study Start

January 22, 2021

Primary Completion

June 29, 2024

Study Completion

June 29, 2024

Last Updated

April 29, 2025

Record last verified: 2025-04

Locations